British Society for Surgery of the Hand Evidence for Surgical Treatment (BEST)

**Topic:** Evidence based management of adult trigger digits

**Date of publication:** October 2016

**Date of anticipated review:** October 2021

NICE has accredited the process used by **British Society for Surgery of the Hand** to produce Clinical Guidelines. Accreditation is valid for 5 years from 10 January 2017. More information on NICE accreditation can be viewed at [www.nice.org.uk/accreditation](http://www.nice.org.uk/accreditation).
Contents

AUTHORS......................................................................................................... 5

GUIDELINE DEVELOPMENT GROUP (GDG):................................................. 5

ROLES OF AUTHORS WHO ARE NOT GDG MEMBERS................................... 6

ACKNOWLEDGEMENTS.................................................................................... 6

FUNDING SOURCES USED.............................................................................. 6

COLLABORATING ORGANISATIONS................................................................. 6

CONFLICTS OF INTEREST ............................................................................. 7

DISCLAIMER..................................................................................................... 7

PROCESS........................................................................................................... 7

OVERALL OBJECTIVE ..................................................................................... 8

ANTICIPATED USERS ..................................................................................... 8

TARGET POPULATION ..................................................................................... 8

QUESTIONS DISCUSSED IN THIS BEST ....................................................... 8

QUESTIONS NOT DISCUSSED IN THIS BEST ................................................ 8
Authors

Rouin Amirfeyz MD MSc FRCS (Trauma & Orth). Consultant Hand and Upper Limb Surgeon, Bristol Royal Infirmary, Bristol. rouin.amirfeyz@uhbristol.nhs.uk

Robert McNinch FRACS (Orth). Upper Limb Fellow, Bristol Royal Infirmary, Bristol. robmcninch@hotmail.com

Adam Watts FRCS (Trauma & Orth). Professor of Upper Limb Surgery, Upper Limb Unit, Wrightington Hospital, Wigan. adam.watts@elbowdoc.co.uk

Nicole Glassey MSc. Hand therapist, Hand Unit, Queen’s Medical Centre, Nottingham. nicole.glassey@nuh.nhs.uk

Justine Bullock MCSP. Hand therapist, Hand Unit, Queen’s Medical Centre, Nottingham. justine.bullock@nuh.nhs.uk

Jeremy Rodrigues BSc MSc PhD MRCS. Academic Clinical Fellow in Plastic Surgery, University of Oxford. j.n.rodrigues@doctors.org.uk

Tim Davis ChM, FRCS. Honorary Professor of Hand Surgery, Queen’s Medical Centre, Nottingham. tim.davis@nuh.nhs.uk

Guideline Development Group (GDG):

Core Stakeholders: Rouin Amirfeyz, GDG Lead

Robert McNinch, Representing Hand Surgery Trainees

Adam Watts, Representing Hand surgeons

Nicole Glassey, Representing Hand therapists

Justine Bullock, Representing Hand therapists
Nigel Andrews, Representing Patients

Special Stakeholders: Mike Taylor (GP), Representing Primary Care

Roles of authors who are not GDG members

Jeremy Rodrigues: Guideline development process expertise (co-author of BEST Process manual)
Tim Davis: Guideline development process expertise (co-author of BEST Process manual)

Acknowledgements

Peter Lanyon: President of the British Society for Rheumatology (representing rheumatologists, whose patients might have trigger digits), provided invaluable advice to the authors and reviewed the draft.

Funding sources used

None

Collaborating organisations

Secondary Care: University Hospitals Bristol NHS Foundation Trust
Nottingham University Hospitals NHS Foundation Trust
Wrightington, Wigan and Leigh NHS Foundation Trust

Primary Care: Bristol Primary Care
Conflicts of interest

There are no conflicts of interest of relevance for any of the GDG members or document authors.

Disclaimer

This document reflects a consensus view of the British Society for Surgery of the Hand Research Committee and Council, based on a systematic and transparent review of evidence. All users of this document must ensure that they consider the entirety of the document when using it, that the recommendations within this guideline are not mandatory, and that clinical judgement and that patient-centred decision making for all individual patients is the highest priority. Users are reminded of their individual duties and responsibilities, professional or otherwise, to use this guideline responsibly and that no content within this guideline overrides these duties and responsibilities.

Process

This document has been produced by systematic reviews, with the interpretation and development of recommendations achieved by consensus of the GDG members.
Overall Objective

The overall objective is to describe the management of adult patients with trigger digits in the United Kingdom.

Anticipated Users

The anticipated users are health care professionals treating patients with trigger digits, those commissioning care for patients with trigger digits, and possibly patients and carers of patients with trigger digits.

Target Population

Adults with trigger digits of the hand.

Questions discussed in this BEST

- Which patients should be referred to hand surgeons?
- Which treatments are superior to other treatments?
- Which treatments are more cost-effective than other treatments?
- What treatments should be offered to patients?
- At what clinical stage should different treatments be offered to patients?
- What outcomes can be expected from particular treatments?
- What future research might be beneficial in clarifying optimal treatment?

Questions not discussed in this BEST

- How should paediatric trigger digits be treated?
Inclusion & exclusion criteria

Patients 16 years and older (adults) with trigger digit (thumb or finger) were included. Paediatric trigger digits were not considered as part of this systematic review.

Plain Language Summary

In a trigger digit, the tendon that pulls the finger towards the palm when making a fist does not slide easily. This leads to clicking when trying to make a fist or straighten the fingers. If bad enough, the finger may not be able to bend or straighten at all.

Different treatments can be used. These include injecting a drug called a steroid through the palm skin towards the tendon, to relieve the trigger digit. The injection can also contain local anaesthetic, a drug that numbs the area. Instead, the point where the tendon is snagging can be surgically released. This can be done using a needle passed back and forth to release around the tendon (“percutaneous release”). Alternatively, a knife can be used in the release, through a cut in the palm (“open release”).

We searched for all studies that compared these kinds of treatments. A group that included a patient, a GP, hand therapists and surgeons then formally discussed the studies in order to agree upon recommendations of how to treat trigger digits. The group’s recommendations are that the injection treatment is reasonable to use in the first instance. If this is not suitable, or if the patient prefers, then the “percutaneous” or “open” release can be used. If the trigger digit does not get better after the injection, then either the “percutaneous” or “open” releases can be used.

Introduction

Trigger digit, or stenosing tenosynovitis, is a condition where abnormal gliding of the flexor tendons within their flexor sheath results in snagging, or locking of the affected digit in flexion, or occasionally, extension. “Triggering” of the affected tendon results in difficulty in flexing or extending the finger and is frequently associated with pain in the palm of the hand. Trigger digit may be associated with disease states such as rheumatoid arthritis and diabetes mellitus (Wolfe 2005). Trigger digit has a reported incidence of 28 cases per 100,000 subjects annually, or a risk of 2.6% over a lifetime (Strom 1977). It is more common in middle-aged women (Lindner-Tons and Ingell
The triggering is most commonly caused by jamming of the flexor tendons in the entrance to the flexor sheath of the digit, most probably due to thickening of the first annular (A1) pulley. It can also arise after injury or an intervention to the tendons (such as repair) that causes it to snag under the pulley. Power grip causes high angular loads at the distal edge of the A1 pulley (Ryzewicz and Wolf 2006). Histologically the A1 pulley may demonstrate fibrocartilagenous metaplasia and hypertrophy, increased glycosaminoglycan, degenerative changes and proliferation of fibrous tissue (Sampson et al 1991). These changes can result in the wall of the A1 pulley becoming three times thicker than normal (Ryzewicz and Wolf 2006).

Although trigger digit is frequently referred to as tenosynovitis, inflammatory changes are not seen histologically in the tenosynovium (Moore 2000) in primary trigger finger. Pathologic inflammatory changes may occur in the surrounding tissues but are not observed in the pulley itself (Ryzewicz and Wolf 2006).

Treatment for trigger finger can be divided into non-operative and operative. Non-operative management includes activity modification, NSAIDs, hand therapy, splinting and corticosteroid injection. Operative management is by release of the A1 pulley, either percutaneously or more commonly with open surgery. Activity modification involves avoiding positions that result in triggering, which may allow the pathologic process to settle. For patients who do not have a contraindication, an oral NSAID can be tried. Hand therapy treatment can include wax therapy, ultrasound, stretching muscle exercises and massage. However, no randomised controlled trials exist in the English literature regarding these forms of non-operative management and so this review will mainly concentrate on corticosteroid and local anaesthetic injection as non-operative interventions and percutaneous and open pulley release as operative interventions of the adult trigger digit. For completeness, these other non-operative treatment modalities, and the evidence behind them, will be discussed.
Methods

Nonoperative treatment:
All randomised controlled trials and controlled clinical trials evaluating the use of splinting, or local injection with corticosteroids, for the treatment of adult trigger finger, were included in this review. Studies focusing on patients older than 16 years with a clinical diagnosis of trigger digit, irrespective of the duration of symptoms, were included. Exclusions included studies focusing on paediatric trigger finger or paediatric trigger thumb. Cochrane Library, Medline, Embase, and Pubmed were used for electronic database searches, coupled with a secondary search of the references of selected articles on 22nd October 2015. Search criteria included using the following terms in the title, abstract and subject headings (exploded); Trigger finger(s) or trigger digit(s) or trigger thumb(s) or stenosing tenosynovitis or stenosing flexor tenosynovitis or stenosing tenovaginitis or flexor tendon entrapment and “non-operative treatment”, “splint or splints” or “treatment or therapeutic”, or “stretching or muscles or muscle stretching exercises”, "wax therapy", "heat or hot temperature", "ultrasound or ultrasound, high intensity focused", "massage", "electrotherapy or electric therapy stimulation" and "acupuncture", and were limited to English language studies and human studies. The search results, prior the exclusions were Medline (641), Embase (780), Pubmed (559) and Cochrane trials database (49), with a total of 129 after the exclusions were applied (Appendix 1). Further specific criteria were then applied to the 129 studies identified. These criteria were that the studies must be randomised, prospective in nature and must have results with at least 85% follow up.

Operative treatment:
A search was performed of the Cochrane Library, Medline, Embase, and Pubmed on 11th March 2015 using the following terms in the title, abstract and subject headings (exploded); Trigger finger(s) or trigger digit(s) or trigger thumb(s) or stenosing tenosynovitis or stenosing flexor tenosynovitis or stenosing tenovaginitis or flexor tendon entrapment and surgery or operative.
The search results were as follows; Cochrane trials database (33), Medline (448), Embase (587), PubMed (450) (figure 2). After exclusion of duplicates, case series, cohort studies, case reports and letters eight articles were included; seven randomised trials and one meta-analysis. A protocol was identified entitled “Surgery
for trigger finger” by Ventin FC et al. however no systematic review has been published in the Cochrane Library.

Shortlisted studies were assessed using SIGN50 methodology.
Systematic review results

Nonoperative treatment:

Two studies were identified which met the criteria. Both of these were controlled trials comparing the efficacy of steroid injections with lidocaine injections in trigger finger in a secondary care setting.

Lambert et al. (1992) compared the effectiveness of intra-tendon sheath injection of methylprednisolone (0.5 ml) combined with 1% lidocaine to 1% lidocaine alone. Treatment success was defined as complete resolution of symptoms or sufficiently improved that further treatment was not necessary one month after injection. Forty-one patients were included in the study, with 20 patients allocated to the steroid and lidocaine injection and 21 patients to an injection of lignocaine alone. The paper states that this allocation was performed randomly, although the specifics of this are not stated. Two patients were lost to follow up from the lidocaine group, leaving a total of 39 patients to be included in the analysis. The outcome assessor was blinded to the treatment group. However, concealment of allocation, blinding of the care provider, blinding of the patients and similarity of groups at baseline regarding most important prognostic indicators were unclear and no intention to treat analysis was used. The results were 45% success (9/20) in the methylprednisolone + lidocaine group and 16% (3/19) in the lidocaine alone group. The absolute risk reduction, or the difference in treatment success between the two groups, was 0.292 (95% CI 0.017 to 0.567), the relative risk, or chance of successful outcome using methylprednisolone combined with lidocaine rather than lidocaine alone, was 2.85 (95% CI 0.91 to 8.96) with a number needed to treat of 3.424 (95% CI 2 to 58). These results demonstrate that a successful treatment at one month after injection is significantly more likely using methylprednisolone combined with lidocaine than with just lidocaine alone. The number needed to treat demonstrates 3.4 patients would need to be injected with methylprednisolone and lidocaine to provide one additional successful treatment at one month compared to the control group.

Murphy et al. (1995) compared the effectiveness of 1ml of betamethasone (1ml celestone equating to 6mg betamethasone) combined with 3ml of 1% lidocaine with injection with 4ml of 1% lidocaine by itself. Twenty-four fingers in 24 patients were randomised into this study with the patients being allocated to the two groups.
depending on whether their initial presentation was on an odd or even date. Fourteen patients were allocated to the steroid and lidocaine group and 10 to the control group. No patients were lost to follow up. Treatment success, defined as participants becoming asymptomatic, was assessed immediately after injection, 3 weeks and 4 months after injection. The outcome assessor and patient were blinded in this study but the care provider was not. 3 of the 14 patients in the steroid group had unrelieved triggering at their 3 week appointment and were reinjected with steroid. Ten of the patients in the steroid group were asymptomatic at this stage and 1 patient had mild triggering. Six of the 10 patients in the control group had unrelieved triggering at their 3 week appointment and were given a steroid injection at that stage. Two of the patients in the control group were asymptomatic at this stage and 2 had mild triggering. The involvement in the study of the patients who received an extra treatment at 3 weeks was ended at this point and they were treated as a failure in their original treatment for statistical purposes. Whilst an intention to treat analysis was used, no concealment of allocation was provided. It was not clear in the study if the two concealment groups were similar at baseline regarding prognostic indicators. Success after 3 weeks was 71% (10/14) in the betamethasone + lidocaine group and 20% (2/10) in the lidocaine alone group. The absolute risk reduction, or the difference in treatment success between the two groups, was 0.514 (95% CI 0.165 to 0.864), the relative risk or chance of successful outcome using betamethasone combined with lidocaine rather than lidocaine alone, was 3.57 (95% CI 0.99 to 12.88) with a number needed to treat of 1.946 (95% CI 1 to 6). Four months after injection therapy treatment success was 64% (9/14) in the betamethasone + lidocaine group and 20% (2/10) in the lidocaine alone group, resulting in a number needed to treat of 2.258 at 4 months. These results demonstrate a successful treatment at 3 weeks and 4 months after injection is significantly more likely using betamethasone and lidocaine than with just lidocaine. The number needed to treat demonstrates 2 patients would need to be injected with betamethasone and lidocaine to provide one additional successful treatment at 3 weeks and 4 months, compared to the control group.

Neither trial specified which specific diagnostic criteria were used for the diagnosis of trigger finger, how many cases were assessed for eligibility prior to enrolment or the demographic and clinical characteristics their two groups. There was also no information regarding the frequency of triggering, severity of pain and functional status of the hands in either study. Both papers mentioned that there were no adverse events or complications but patient satisfaction with the treatment was not
assessed. No power calculation was performed and no validated patient based outcome measure was used.

Pooling of the data results in 63 participants. Corticosteroid injections with lidocaine showed significantly more effectiveness within 4 weeks than lidocaine injection alone (RR 3.15, 95% CI 1.34 to 7.40). (Peters-Veluthamaningal et al. 2009).

These studies demonstrate that there is moderate evidence for superiority of a mixture of corticosteroid and lidocaine injections over injections with lidocaine alone. It is noted that although the patients benefited from the corticosteroid and lidocaine injection, the difference between the groups was the addition of corticosteroid. It is unclear from the existing evidence base whether corticosteroid alone as an injection would be effective, or whether combining corticosteroid with local anaesthetic (which has other effects such as increasing the volume injected) is necessary.

Neither study reported any adverse effects. As the numbers are small these effects need to be confirmed in larger, well-designed randomised trials. The results also suggest efficacy up to four months, but long-term efficacy still remains to be clarified.

Operative treatment:

Of the randomised trials 4 were assessed as of acceptable quality to minimise bias (Gilberts et al 2001, Chao et al 2009, Zyluk and Jagieski 2011, Sato et al 2012). Three randomised controlled trials were excluded because the methodology was assessed as introducing a high or uncertain risk of bias. This was because of poor randomisation concealment, differences in the groups after randomisation, and measurement of outcomes (Maneerit et al 2003, Dierks et al 2008, Bamroogshawgasame 2010).

The one meta-analysis (Wang et al. 2013) was assessed as high quality with a low probability of bias.

Percutaneous versus Open Release

Gilberts et al. (2001) conducted a randomised trial of percutaneous trigger finger release versus open surgery in a total of 100 digits followed for 12 weeks. They found no difference in recurrence rates, which were very low. The duration of surgery, recovery of motor function and time to return to work were all significantly
shorter in the percutaneous group. A further randomised trial compared percutaneous, open pulley release and steroid injection (Sato et al 2012) in 150 digits followed for 6 months. The study population was over the age of 15 years. The authors reported equivalent outcome with no recurrences in the percutaneous or open surgical arm of the trial, but percutaneous release resulted in better finger movement in the first two post-operative months. No complications were encountered.

Injection versus Percutaneous Release

Two studies met the inclusion criteria. Chao et al. (2009) reported on a trial in 97 thumbs (86 patients) randomised to percutaneous release with a miniscapel versus steroid injection. Whilst the study was well designed a significant number of patients were lost to follow up in the steroid injection cohort (32% of digits lost at 12 months compared to no loss to follow up in the percutaneous release arm). Zyluk et al. (2011) similarly compared percutaneous release to steroid injection in a cohort of 115 patients with trigger digit and reported recurrence rates of zero in the percutaneous release and 12% in the injection arm of the trial. Lost to follow up rates were also high at 22% lost from the percutaneous release arm and 13% from the injection arm at final review at 6 months. No complications were reported.

Wang et al. (2013) conducted a meta-analysis of seven randomised controlled trials to ascertain the best treatment method for trigger digit by determining the risk ratio of treatment failure, level of satisfaction and complications comparing percutaneous release, open surgery and steroid injections. A total of 397 were enrolled in randomised trials comparing percutaneous release and open surgery. For comparison of percutaneous release and steroid injection four trials included 417 patients. The authors found no difference in treatment failure between percutaneous and open surgery with follow up times between 2 and 6 months. Treatment failure rates were higher in the group who had steroid injections compared to those who had percutaneous release who were also more likely to be satisfied with the outcome at follow-up times of 6 to 23 months. There were no differences in complication rates reported. It should be noted that this meta-analysis included all the trials mentioned above and also some trials excluded from this review due to risk of bias.
Other nonoperative treatment modalities (not included in the systematic review):

There are no robustly performed, randomised controlled trials in the English literature on other aspects of non-operative management which fit the inclusion criteria of this systematic review. However, the evidence for other treatment modalities shall be reviewed.

Splinting

Proponents of splinting state that it alters the biomechanics of the flexor tendons, which reduces friction between the tendons and pulley system, while encouraging maximal differential tendon glide. By altering the mechanical pressures of the proximal pulley system and encouraging maximal tendon gliding, the pathologic state of the tendon and its sheath may be reversed in a significant number of cases (Creighton et al 1990). Splint wear is usually advised for a 3 to 9-week period (Evans et al 1988, Creighton et al 1990 and Cannon et al 1991). It is usually not necessary to splint adjacent fingers (Evans et al 1988). Most studies looking at splinting to treat trigger finger have focused on splinting of the metacarpophalangeal (MCP) joint. However, there is some disagreement on the degree of joint positioning and there are also advocates for splinting of the distal interphalangeal (DIP) joints (Colbourne et al 2008).

When the MCP joint was splinted the position varied between 0 and 15 degrees of flexion, allowing for full interphalangeal movement (Lindner-Tons and Ingell 1998, Patel and Bassini 1992, Evans et al 1988). Studies on the efficacy of splinting report good outcomes in 70-73% of their patients (Patel and Bassini 1992, Evans et al 1988).

In the Evans et al study the MCP joint was immobilised in 0 degrees using a volar-based hand splint allowing full movement in the proximal and distal interphalangeal joints. Evans et al. demonstrated a 73% success rate using a splint combined with hook and fist exercises, in a study of 55 digits in 38 patients (1988). However, splinting was initiated at differing times from the onset of triggering in a heterogeneous group of patients and there was no data on recurrence following discontinuation of the splint. The assessment and outcome measures were also subjective and the methodology lacked detail, making it difficult to repeat. Patel and
Bassini reported a 70% successful outcome with splinting the MCP joint for 6 weeks in 10-15 degrees of flexion in 40 fingers (1992). They found that splinting was successful in 77% of the patients whose symptoms had been present six months or less and 44% of those patients with symptoms longer than six months. Patel and Bassini (1992), and Lindner-Tons and Ingell (1988) have suggested a higher compliance rate with splinting in 10-15 degrees of MCP joint flexion compared with 0 degrees to allow increased function of the hand.

Colbourne et al. studied the effectiveness of an MCP joint blocking splint with the MCP joints positioned in 10-15 degrees of flexion (2008). Patients were instructed to wear splints day and night for 6 weeks and this was extended to 10 weeks if triggering persisted. Subjects removed the splint three times a day to perform passive IP joint flexion, composite full flexion, full extension plus active hook fist. 93% of the participants reported improvements in triggering as a result of the splint. However, 57% of subjects did not comply with splint use due to interference with function and the majority did not follow the exercise program.

Rodgers et al. believed that the FDP tendon, either alone or in conjunction with the FDS tendon, was instrumental in the pathogenesis of trigger finger (1998). They used a distal interphalangeal (DIP) splint made from alumafoam taped to the dorsum of the digit or a Stack finger splint, as well as NSAIDs in their treatment of 21 patients with trigger finger. Their protocol consisted of full-time splint wear for at least six weeks. They demonstrated 55% resolution of the triggering.

Splint design has been attributed to patient compliance rates. The splint should be of the lowest profile and least restrictive design possible, since it should be worn for the entire day for a number of weeks (Lindner-Tons and Ingell 1998). Poor design leads to non-compliance with splint wear before it has had a chance to prove effective. Some splints maintain the optimal finger position but bulky strapping over the dorsum of the hand, as well as extensive palmar coverage often compromise compliance (Evans et al 1988, Cannon et al 1991, Patel and Bassin 1992). Alternative splint designs have been postulated to minimise interruptions with activities of daily living (Lindner-Tons and Ingell 1998).

Although splinting to treat trigger finger has been described as inexpensive and helpful in reducing symptoms of triggering with minimal complications (Evans et al 1988, Lindlor-Tons and Ingell 1998, Colbourne et al 2008, Rogers et al 1998) a review of the literature shows little comprehensive or objective data to clearly support the role of splinting. Tarbhai et al. attempted to compare different splint designs to determine whether MCP joint or DIP joint blocking splints were more effective (2012).
They also attempted to compare the splint designs with respect to comfort, compliance and usefulness during functional activities. They prospectively randomised 30 subjects to MCP or DIP joint blocking splints and found that the MCP joint splint provided at least partial relief of triggering and pain in 10 of 13 patients, whereas the DIP joint splint provided at least partial relief of triggering and pain in 7 of 15 patients after 6 weeks treatment. There was statistically significant improvement in both groups at 6 weeks, which was maintained in a minority of the cohort for 1 year. There was little difference between the two groups with regards to impact on function. Patients who wore the MCP joint splint reported higher rates of comfort compared to those who wore the DIP joint blocking splint. Joint stiffness was reported in both groups (1 of 13 in the MCP joint group and 7 of 15 in the DIP joint group). However, this resolved once the splints were discontinued.

The European Handguide Study aimed to provide guidelines on treatment for trigger finger based on the consensus of the Delphi group, a group of 35 experts in the field. They found no evidence for the effectiveness of splinting in a systematic review (Huisstede et al 2010). They felt that an MCP joint blocking splint at 0 degrees was preferable but no consensus could be achieved on the optimal orthotic regimen including duration of splint wear during the day or number of weeks of splint usage. The length of time and cost required for producing and maintaining a splint compared with the application of a single steroid injection should be considered. A patient on average needs to seen by a qualified therapist four times and have a splint made (at least one if no further adjustment required). This would cost £110 minimum. Also the potential detrimental effects on adjacent digits and hand function with long term use of splintage should not be overlooked.

Hand therapy

There is minimal evidence for the use of hand therapy techniques, such as heat, stretching, wax therapy, ultrasound and massage, as well as other techniques such as electrotherapy and acupuncture. Proponents of techniques involving therapeutic heat modalities state that it increases blood flow to the area, facilitates collagen plasticity and helps with resolution of oedema (Salim et al 2011). Combining heat with stretching allows plastic deformation of collagen (Cameron 1999, Knight et al 2001, Recor and Johnson 2010). Massage has been claimed to ‘soften’ or remodel tendons reducing tissue bulk at the pulleys (Evans et al 1988). The net result of these techniques being that the tendon passes more easily through the A1 pulley.
Salim et al attempted to compare the effectiveness of hand therapy with corticosteroid injections in the management of mild trigger fingers, defined as patients with mild crepitus on flexor tendon gliding, uneven finger movements or actively correctable triggering (2011). Eight-four patients were randomised to either corticosteroid injection or hand therapy. The randomisation was performed numerically, with the first five patients being allocated to hand therapy, the next five patients to corticosteroids and so on. Ten patients were lost to follow up leaving 35 patients in the hand therapy group and 39 in the corticosteroid group. The hand therapy regimen provided is unclear, being stated as consisting of ten sessions, comprising wax therapy, ultrasound, muscle stretching exercises and massage. The specific treatment, duration or technique used in these categories is not defined. The steroid injection comprised 1ml of triamcinolone acetonide and 1ml of 2% lidocaine injected at the A1 pulley. Whether the injection was injected deep, or superficial, to the sheath is not clear. The patients were followed up at 6 weeks and 3 months, and a telephone interview was used at 6 months to assess recurrence of pain and triggering. The authors quoted an overall success rate, defined as absence of pain and triggering, of 68.6% in the hand therapy group and 97.4% in the corticosteroid group at 3 months. No complications were noted in either group. At 6 months no patients in the hand therapy group had any recurrence of symptoms but 6 patients in the corticosteroid group had developed pain and 4 had developed symptoms of triggering. Since this was performed by telephone interview this could not be correlated clinically. The results of this study are compromised by the lack of detail regarding the hand therapy treatments and the fact that multiple hand therapy techniques are used rather than just one. This, however, is the only published study regarding the outcome of these hand therapy techniques in trigger finger. There are no studies which independently assess wax therapy, heat therapy, muscle stretching, ultrasound, massage, electrotherapy or acupuncture as the primary treatment modality in trigger finger.

Systematic review overview discussion:

Systematic review of the published literature has identified a reasonable number of trials of acceptable quality to answer the questions outlined for operative management but not for nonoperative management. The data indicated that open and percutaneous releases are associated with a similar low risk of recurrence of
trigger finger or thumb in adults. Similarly, at six months there is no evidence for a
difference in pain scores although the initial pain scores may be lower after
percutaneous treatment. There is no evidence of an increased risk of complications
with either treatment. Local steroid injection carries a greater risk of recurrent or
persistent symptoms.

There is a paucity of quality evidence in the English literature regarding non-
operative management of trigger finger. Splinting is non-invasive and may provide
short-term relief, but evidence for its use is poor. There is no evidence for the use of
other non-invasive treatment modalities.

There is moderate evidence that corticosteroid injections are effective for the
treatment of trigger finger, but the implications for daily clinical practice may be
limited by the fact that the evidence is based on two small studies of poor quality,
performed in the setting of secondary care, and there were only data available for
effectiveness up to four months. Complications from steroid injections are rare but
may include fat necrosis, skin depigmentation and rupture of the flexor tendons
(Ryzewicz and Wolf 2006), none of which were specifically encountered or reported
in the two mentioned studies. However, corticosteroid injection is an easily applicable
treatment modality, inexpensive and less invasive than surgery. Corticosteroid and
anaesthetic injection is a reasonable first line option of treatment as the NHS cost of
trigger finger release in England is presently between £867.26 to £945.31 depending
on co-morbidities (data obtained from University Hospitals Bristol NHS Foundation
Trust, Management Accountant, Surgery Head & Neck Division, 24th February
2016). Compared with surgery, there is high evidence that local corticosteroid
injection is associated with increased rates of ongoing or recurrent symptoms at a
minimum of six months after intervention Both of the included studies were in a
secondary care setting, and this could potentially be offered in primary care, although
there would need to be considerable training for providers. As it stands, injection for
trigger finger and/or thumb is not offered by many first line services due to lack of
time, expertise or resources.

There is high quality evidence that trigger digit can be managed safely by open or
percutaneous surgical release.
Clinical practice recommendations:

Based on the current available evidence, it is reasonable to offer corticosteroid and local anaesthetic injection as the first line of treatment (moderate evidence). Percutaneous release may be offered by an appropriately trained practitioner (high evidence).

If symptoms fail to resolve, or should the patient decide against injection, then the next line of treatment may be either an open or percutaneous release of the constricted pulley (high evidence). Other treatment modalities are not currently supported.

Good practice points:

It is considered good practice that:

- in the absence of contraindication and with patient’s agreement, the first line of treatment for an adult trigger digit should be a single injection of steroid and local anaesthetic. However, an outpatient percutaneous release can be offered if the practitioner is qualified and experienced in the procedure.
- a referral to the secondary care should be made if the patient prefers a percutaneous or open release.
- a referral to secondary care for surgical treatment (percutaneous or open depending on the available expertise) should be made it the triggering recurs after injection.

Clinical audit indicators:

It is considered that the following could be used as clinical audit indicators:

- Recurrence (as the primary outcome)
- Patient satisfaction (one example would be Patient Global Impression of Change)
- Pain score
Resource Implications:

It is believed that the clinical practice recommendations and good practice points either align with existing NHS practice, or are less expensive than current practice (e.g. increasing the use of steroid injection as first line treatment rather than surgery is anticipated to reduce costs). Therefore, the resource implication of implementing this guideline is considered minimal. However, training of clinical staff in the technique of steroid injection ay be required in some settings.

Facilitators and barriers to implementation:

If clinical staff are not competent in injection, then training may be required. Such training is not believed to be complex, expensive or onerous to deliver. No other significant barriers to implementation have been identified. It is suggested that using the quick reference as a standalone reference may be facilitator. For example, users may wish to make the quick reference guide could be made available in clinical areas.

Future research recommendations:

Areas for future research into the management of trigger finger include large, well designed, randomised controlled trials of:

- surgery versus corticosteroid injections with outcomes measured beyond four months;
- corticosteroid versus corticosteroid combined with local anaesthetic (the latter was used in all studies which satisfied the entry criteria for our systematic review;
- DIP joint and MCP joint splints with corticosteroid injection;
- individual hand therapy treatment modalities.
- Treatment of trigger fingers in those with rheumatoid arthritis and diabetes mellitus
- Treatment strategies involving more than one injection containing steroid (i.e. giving a second or even third steroid injection)
Stakeholders invited to provide external review:

The British Orthopaedic Association
The British Association of Plastic, Reconstructive and Aesthetic Surgeons
The British Association of Hand Therapists
The Royal College of General Practitioners
The British Society for Rheumatology

Timeline of guideline:

Date topic identified: 27/03/2013
Date GDG lead appointed: 07/04/2013
Date draft supplied by GDG authors: 08/08/2016
Date Internal review completed: 21/08/2016
Dates of public consultation: 30/08/16 – 16/09/16
Date external review completed: 22/09/16
Date published: 13/10/16
Appendix 1: PRISMA flow charts for systematic review

Flow Diagram Operative Management

Records identified through database searching
(n = 1518)

Records after duplicates removed
(n = 634)

Records screened
(n = 634)

Full-Text articles assessed for eligibility
(n = 9)

Studies included in qualitative synthesis
(n = 4)

Records excluded
(n = 625)

Full-text articles excluded
(n = 5)
Appendix 2: Evidence Summary Table


(Four operative primary research articles, two nonoperative primary research articles, one meta-analysis)
<table>
<thead>
<tr>
<th>Study details</th>
<th>Population and setting</th>
<th>Method of allocation</th>
<th>Outcome measures and length of f/u</th>
<th>Results</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gilberts et al (2001) The Netherlands Percutaneous vs open release</td>
<td>Digits</td>
<td>Randomisation using sealed envelopes 46 digits open surgery, 54 digits percutaneous (18 gauge needle). All using 1% lidocaine</td>
<td>Operation time Duration of postop pain Recovery of ROM Return to work F/u: Ten days, six weeks and Three months</td>
<td>Operation time 4 min shorter in percutaneous (p&lt;0.0001) Postop pain period 1.6 days shorter in percutaneous (p=0.039) Recovery of ROM 11 days shorter in percutaneous (p&lt;0.002) Return to work 3.6 days shorter in percutaneous (p&lt;0.0001)</td>
<td>Assessors and patients not blinded No p values provided for baseline groups comparisons Duration of symptoms 6 months longer in open group compared to percutaneous</td>
</tr>
<tr>
<td>Chao et al (2009) China Percutaneous vs steroid injection</td>
<td>Thumbs</td>
<td>Randomisation using sealed envelope (witnessed) 46 thumbs percutaneous (Mini Scalpel Needle) 47 thumbs injection (1 ml triamcinolone)</td>
<td>Success, which was defined as VAS for pain &lt;1 and no triggering Percentage change in pain Complications Patient satisfaction F/u: One month and</td>
<td>At one year 44/46 in percutaneous and 12/47 in steroid groups were successfully treated. At one year percentage change for VAS pain was 89.4 for</td>
<td>At one year 46 thumbs in percutaneous group were assessed despite they said one loss to f/u, but only 32 in steroid group were followed despite they claimed 3 loss to f/u</td>
</tr>
<tr>
<td>Disease</td>
<td>One Year</td>
<td>Percutaneous and 6.8 for steroid (p&lt;0.01) At one year 44/46 were satisfied in percutaneous versus 12/47 in steroid group (p&lt;0.01) No complications seen in any group</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------</td>
<td>----------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Zyluk and Jagielski (2011) Poland Percutaneous vs steroid injection | Digits Included: Adult patients (youngest 19 y/o) with trigger digits (all grades) Excluded: Not mentioned Hospital outpatient | Randomisation using sealed envelope (witnessed) 55 digits percutaneous (19 gauge needle) 60 digits injection (1 ml betamethasone) | Recurrence (return to baseline grade of triggering after total or partial improvement) VAS for pain AROM Grip strength (percentage of the other side) Complication F/u: One and six months | At six months, six recurrences were seen in steroid group vs none in percutaneous (p=0.005) At six months steroid group showed 0.9 point less in Vas for pain which was statistically significant (no p value provided) At six months steroid group showed 5 degrees more in AROM which was statistically significant (no p | More severe triggering in percutaneous group 0.9 difference in VAS for pain and 5 degrees in total AROM of digit is not clinically significant
<table>
<thead>
<tr>
<th>Authors</th>
<th>Studies</th>
<th>Design</th>
<th>Inclusion criteria</th>
<th>Exclusion criteria</th>
<th>Setting</th>
<th>Randomisation</th>
<th>Treatment allocation</th>
<th>Primary outcomes</th>
<th>Secondary outcomes</th>
<th>Complications</th>
<th>Follow-up</th>
<th>Power calculation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sato et al (2012) Brazil</td>
<td>Open vs percutaneous vs steroid injection</td>
<td>Randomisation via sequentially numbered sealed envelopes. 6-sided dice was used initially for each envelope treatment allocation.</td>
<td>Digits Included: Age &gt; 15 y/o with grade II-IV on Quinnell classification Excluded: Grade I triggering on Quinnell classification or previous treatment of triggering (any form) Hospital setting</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Primary: Cessation of triggering for 6 months Secondary: Pain (A1 pulley region and joint IP/PIP) Total active motion Complication</td>
<td>F/u: 1 &amp; 2 weeks, 1, 2, 4 &amp; 6 months (if second steroid injection needed then 6 months from the second injection)</td>
<td>100% &quot;cure rate&quot; in open and percutaneous vs 57% after one injection and 86% after two (p=0.004) A1 pulley site and IP/PIP joint pain was more in the open and percutaneous surgery group compared to steroid injection in the first two months (p=0.008 &amp; 0.029) but the same after two months Lower total active motion in open surgery group in</td>
<td>Power calculation: 43 in each group</td>
<td></td>
</tr>
</tbody>
</table>
**Wang et al (2013)**  
China  
Meta-analysis of open vs percutaneous vs steroid injection  

| Study Details | Study Design | Study Inclusion | Study Exclusion | Study Quality | Analysis Method | Complications | Patient Satisfaction | Patient satisfaction more in percutaneous group compared to steroid injection group (RR=2.01, 95% CI 1.62-2.48, p<0.001)  
No difference in failure of complications between open and percutaneous groups (p=0.94 & 0.84) but significantly more common in steroid injection group (p<0.001)  
Pain score, grip strength, active range of movement, active range of movement, operative time & costing not analysed due to inconsistency of the data in the literature |
|---|---|---|---|---|---|---|---|
Study inclusion: RCTs or quasiRCTs comparing open, percutaneous or steroid injection in adult trigger digits  
Excluded: Letters, review articles, children trigger digits, case reports or cadaveric studies  
Study quality: Evaluated using Detsky Quality Scale | Tested for homogeneity: I², if over >50% then random effect Mantel-Haenszel model used  
Analysis method: RR with 95% CI for dichotomous variables, weighted test with forest plots | Number of failures | F/u: All data for 6 months | the first two months (p=0.048) but the same in all afterwards  
No complications in any group |
| Lambert et al (1992)  
UK | Methylprednisolone | Digits  
Included: 18 y/o or over, trigger digit for at least 3 months  
20 digits received methylprednisolone with | Randomised  
Patients kept diary of pain, analgesic consumption and episodes of locking or stiffness | 45% initial steroid group had resolved symptoms compared with 16% control  
Method of randomisation for allocation not specified |

Lambert et al (1992)  
UK  
Methylprednisolone  

| Study Details | Study Design | Study Inclusion | Study Exclusion | Study Quality | Analysis Method | Complications | Patient Satisfaction | Patient satisfaction more in percutaneous group compared to steroid injection group (RR=2.01, 95% CI 1.62-2.48, p<0.001)  
Pain score, grip strength, active range of movement, active range of movement, operative time & costing not analysed due to inconsistency of the data in the literature |
<table>
<thead>
<tr>
<th>Study</th>
<th>Design</th>
<th>Treatment</th>
<th>Inclusion Criteria</th>
<th>Exclusion Criteria</th>
<th>Follow-up</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>acetate plus 1% lidocaine vs 1% lidocaine alone</td>
<td>Hospital outpatient</td>
<td>acetate plus 1% lidocaine vs 1% lidocaine alone</td>
<td>least 3 months Excluded: insulin-dependent diabetics, patients with RA or eczema, patients with a concurrent infection, those who had undergone injection in the previous 3 months.</td>
<td></td>
<td>Clinical assessment at follow up. F/u: 1 month following injection. Graded as a success if no further treatment required. Those with some improvement were injected with methylprednisolone, those with no improvement were listed for surgery</td>
<td>Subsequent steroid group had 60% resolved symptoms (p&lt;0.02).</td>
</tr>
<tr>
<td>Murphy et al (1995) USA</td>
<td>Hospital outpatient</td>
<td>6mg celestone (3ml) plus 1ml 1% lidocaine vs 4ml 1% lidocaine</td>
<td>Digits Included: 18 y/o or over, trigger digit Excluded: patients with RA, diabetes mellitus, previous tendon laceration, previous trigger finger injection or patients with unrelievable locking</td>
<td></td>
<td>Subjective grading of pain and triggering provided by the patient before and after the injection. Clinical examination by blinded examiner at f/u F/u: 3 weeks after injection, and 4 months</td>
<td>10 of 14 patients in the steroid group asymptomatic at 3 months, 3 had unrelieved triggering, 1 had mild triggering. 2 of the 10 placebo patients were asymptomatic at 3 months, 2 had mild triggering, 6 had no relief. At 4 months, 9 of the 10 patients in the</td>
</tr>
</tbody>
</table>

**Notes:**
- F/u: Follow-up
- Trigger thumb accounted for 30% digits
- 2 patients in the lidocaine group lost to follow up and excluded
- Assessor at 1 month blinded to patient allocation
steroid group remained asymptomatic (64% of the 14 patients) and 2 of the 10 placebo patients remained asymptomatic (20%), p< 0.05
Appendix 3: Key clinical practice recommendations

1. In the absence of contraindication and with patient’s agreement, the first line of adult trigger digit should be a single steroid and local anaesthetic injection. A percutaneous release in outpatients may be offered if the practitioner is qualified and experienced in the procedure (moderate evidence).

2. If the patient prefers percutaneous or open release, referral to secondary care should be made (high evidence).

3. A referral to secondary care for surgical treatment (percutaneous or open depending on the available expertise) should be made (high evidence) if symptoms fail to resolve, or if there is recurrence.
Appendix 4: Patient flow algorithm

1. Symptomatic Adult Trigger Digit
   - Steroid and Local Anaesthetic Injection is Offered
     - Patient Agrees to Proceed
       - Settled
         - Observation by Patient (to return of any concerns)
       - Recurrence or Failure
         - Surgery (Open or Percutaneous)
     - Patient Declines or Injection Contraindicating
Appendix 5: Support Tool: Quick reference guide
Key clinical practice recommendations:

1. In the absence of contraindication and with patient's agreement, the first line of adult trigger digit should be a single steroid and local anaesthetic injection. A percutaneous release in outpatients may be offered if the practitioner is qualified and experienced in the procedure (moderate evidence).

2. If the patient prefers percutaneous or open release, a referral to secondary care should be made (high evidence).

3. A referral to secondary care for surgical treatment (percutaneous or open depending on the available expertise) should be made (high evidence) if symptoms fail to resolve, or if there is recurrence.
Appendix 6: Characteristics of included studies
<table>
<thead>
<tr>
<th>Study details</th>
<th>Population and setting</th>
</tr>
</thead>
</table>
| **Gilberts et al (2001)**  
The Netherlands  
Percutaneous vs open release | Digits  
Included: 18 y/o or over, trigger digit for over 1 month  
Excluded: Previous surgery on the same digit, connective tissue disease including RA  
Outpatient surgical facility |
| **Chao et al (2009)**  
China  
Percutaneous vs steroid injection | Thumbs  
Included: Idiopathic adult trigger thumb with uneven movement +/- intermittent locking  
Excluded: RA, diabetes mellitus, chronic systemic disease  
Hospital outpatient |
| **Zyluk and Jagielski (2011)**  
Poland  
Percutaneous vs steroid injection | Digits  
Included: Adult patients (youngest 19 y/o) with trigger digits (all grades)  
Excluded: Not mentioned  
Hospital outpatient |
| **Sato et al (2012)**  
Brazil  
Open vs percutaneous vs steroid injection | Digits  
Included: Age > 15 y/o with grade II-IV on Quinell classification  
Excluded: Grade I triggering on Quinell classification or previous treatment of triggering (any form)  
Hospital setting |
| **Wang et al (2013)**  
China | Meta-analysis  
Literature search: PubMed, Embase & Cochrane library up to October 2012 |
| Meta-analysis of open vs percutaneous vs steroid injection | Study inclusion: RCTs or quasiRCTs comparing open, percutaneous or steroid injection in adult trigger digits  
Excluded: Letters, review articles, children trigger digits, case reports or cadaveric studies  
Study quality: Evaluated using Detsky Quality Scale |
|---|---|
| Lambert et al (1992)  
UK  
Methylprednisolone acetate plus 1% lidocaine vs 1% lidocaine alone | Digits  
Included: 18 y/o or over, trigger digit for at least 3 months  
Excluded: insulin-dependent diabetics, patients with RA or eczema, patients with a concurrent infection, those who had undergone injection in the previous 3 months.  
Hospital outpatient |
| Murphy et al (1995)  
USA  
6mg celestone (3ml) plus 1ml 1% lidocaine vs 4ml 1% lidocaine | Digits  
Included: 18 y/o or over, trigger digit  
Excluded: patients with RA, diabetes mellitus, previous tendon laceration, previous trigger finger injection or patients with unrelievable locking  
Hospital outpatient |
Appendix 7: Quality of evidence assessment of included studies
<table>
<thead>
<tr>
<th>Study details</th>
<th>Design</th>
<th>Quality</th>
<th>Consistency</th>
<th>Directness</th>
<th>Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gilberts et al (2001)</td>
<td>Randomisation using sealed envelopes</td>
<td>Some concerns (assessors and patients not blinded, no p values provided for baseline groups comparisons)</td>
<td>No important inconsistency</td>
<td>Some uncertainty (duration of symptoms 6 months longer in open group compared to percutaneous)</td>
<td>High</td>
</tr>
<tr>
<td>Percutaneous vs open release</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chao et al (2009)</td>
<td>Randomisation using sealed envelope (witnessed)</td>
<td>More loss to follow up in steroid group</td>
<td>No important inconsistency</td>
<td>Some uncertainty (only thumb included)</td>
<td>High</td>
</tr>
<tr>
<td>Percutaneous vs steroid injection</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zyluk and Jagielski (2011)</td>
<td>Randomisation using sealed envelope (witnessed)</td>
<td>Randomisation using sealed envelope (witnessed)</td>
<td>No important inconsistency</td>
<td>Potential uncertainty (no mention of exclusions)</td>
<td>High</td>
</tr>
<tr>
<td>Percutaneous vs steroid injection</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sato et al (2012)</td>
<td>Randomisation via sequentially numbered sealed envelopes. 6-sided dice was used initially for each envelope treatment allocation</td>
<td>No serious limitations</td>
<td>No important inconsistency</td>
<td>No serious indirectness</td>
<td>High</td>
</tr>
<tr>
<td>Open vs percutaneous vs steroid injection</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wang et al (2013)</td>
<td>Meta-analysis</td>
<td>No serious limitations</td>
<td>Some uncertainty due to varied reported outcome measures in baseline studies</td>
<td>No serious indirectness</td>
<td>High</td>
</tr>
<tr>
<td>Meta-analysis of open vs percutaneous vs steroid injection</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lambert et al (1992)</td>
<td>Randomised</td>
<td>Potential concerns (allocation method not)</td>
<td>No important inconsistency</td>
<td>Serious concerns (very short follow up)</td>
<td>Medium</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Steroid &amp; LA vs LA</td>
<td>specified)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------------</td>
<td>-------------</td>
<td>-------------</td>
<td>----------------</td>
<td>----------------</td>
<td></td>
</tr>
<tr>
<td>Murphy et al (1995)</td>
<td>Randomised</td>
<td>Serious concerns (allocation bias, small numbers)</td>
<td>No important inconsistency</td>
<td>Some concerns (short follow up)</td>
<td>Medium</td>
</tr>
</tbody>
</table>
Appendix 8: Included study references


Murphy D., Failla J., Koniuch M., Steroid versus placebo injection for trigger finger. The Journal of Hand Surgery 1995; 20(4); 628-31


Appendix 9: Other references


Cameron M., Physical agents in rehabilitation: From research to practice. WB Saunders, 1999, p.149-73


Knight C., Rutledge C., Cox M., et al., Effect of superficial head, deep heat and active exercise warm-up on the extensibility of the plantar flexors. Phys Ther. 2001, 81: 1206-14


SIGN50 http://www.sign.ac.uk/guidelines/fulltext/50/


Sweezy R., Trigger finger splinting. Orthopedics 1999; 22(2) 180
